Potentials of medicinal mushroom bioactives as complementary and alternative medicine in cancer therapy: an overview of experimental and clinical evidence
Traditional Medicine Research · 2027 · 12 (5) · 31
DOI: 10.53388/tmr2027031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Traditional Medicine Research, 2027. Verfasst von Kainoor Krishnankutty Janardhanan und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Medicinal mushrooms have emerged as promising complementary agents in cancer therapy because of their diverse bioactive constituents, including β -glucans, polysaccharides, triterpenoids, phenolic compounds, and proteins, which exhibit immunomodulatory and anticancer activities. Increasing experimental and clinical evidence demonstrates that these bioactives suppress tumor growth by regulating key oncogenic pathways, including PI3K/Akt/mTOR, NF-κ B, MAPK, p53, and estrogen receptor signaling, while promoting apoptosis, inhibiting angiogenesis and metastasis, and enhancing antitumor immunity. Recent studies further indicate that mushroom-derived β -glucans may improve responses to immune checkpoint inhibitors by overcoming resistance to PD-1/PD-L1-targeted therapies, highlighting their potential role in modern cancer immunotherapy. In addition, several mushroom-derived compounds modulate multidrug resistance through inhibition of ATP-binding cassette transporters and associated survival signaling pathways, thereby enhancing the efficacy of conventional chemotherapy. Clinical investigations have primarily evaluated preparations from Lentinula edodes , Ganoderma lucidum , Trametes versicolor , and Grifola frondosa , demonstrating improvements in quality of life, immune function, treatment tolerance, and, in selected cancers, clinical outcomes when used as adjuncts to standard therapy. This review integrates current experimental, mechanistic, and clinical evidence with particular emphasis on multidrug resistance modulation, immune checkpoint-related mechanisms, and emerging structure–activity relationships governing the anticancer activities of mushroom-derived bioactives. It also discusses the major translational challenges, including structural heterogeneity, bioavailability, and standardization, that must be addressed to facilitate their development as evidence-based complementary anticancer therapeutics.
Zitieren
APA
Janardhanan, K. K., Das, S., & Ajith, T. A. (2027). Potentials of medicinal mushroom bioactives as complementary and alternative medicine in cancer therapy: an overview of experimental and clinical evidence. Traditional Medicine Research, 12(5), 31. https://doi.org/10.53388/tmr2027031
Vancouver
Janardhanan KK, Das S, Ajith TA. Potentials of medicinal mushroom bioactives as complementary and alternative medicine in cancer therapy: an overview of experimental and clinical evidence. Traditional Medicine Research. 2027;12(5):31. doi:10.53388/tmr2027031
BibTeX
@article{Janardhanan2027,
author = {Janardhanan, Kainoor Krishnankutty and Das, Sneha and Ajith, Thekkuttuparambil Ananthanarayanan},
title = {Potentials of medicinal mushroom bioactives as complementary and alternative medicine in cancer therapy: an overview of experimental and clinical evidence},
journal = {Traditional Medicine Research},
year = {2027},
volume = {12},
number = {5},
pages = {31},
doi = {10.53388/tmr2027031}
}
EUVIMED